The DOI matches its Crossref record; 859 of the 859 references it cites were found in a registry or an index.
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Open accessAbstract
Receptor tyrosine kinases (RTKs), a category of transmembrane receptors, have gained significant clinical attention in oncology due to their central role in cancer pathogenesis. Genetic alterations, including mutations, amplifications, and overexpression of certain RTKs, are critical in creating environments conducive to tumor development. Following their discovery, extensive research has revealed how RTK dysregulation contributes to oncogenesis, with many cancer subtypes showing dependency on aberrant RTK signaling for their proliferation, survival and progression. These findings paved the way for targeted therapies that aim to inhibit crucial biological pathways in cancer. As a result, RTKs have emerged as primary targets in anticancer therapeutic development. Over the past two decades, this has led to the synthesis and clinical validation of numerous small molecule tyrosine kinase inhibitors (TKIs), now effectively utilized in treating various cancer types. In this manuscript we aim to provide a comprehensive understanding of the RTKs in the context of cancer. We explored the various alterations and overexpression of specific receptors across different malignancies, with special attention dedicated to the examination of current RTK inhibitors, highlighting their role as potential targeted therapies. By integrating the latest research findings and clinical evidence, we seek to elucidate the pivotal role of RTKs in cancer biology and the therapeutic efficacy of RTK inhibition with promising treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 859
Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes
Cheon, H., & Stark, G. R. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903487106 · Cited by 305
Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70244-x · Cited by 304
Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit
Lennartsson, J., Jelacic, T., Linnekin, D., & Shivakrupa, R. (2005) · STEM CELLS · doi:10.1634/stemcells.2004-0117 · Cited by 303
Papa, A., & Pandolfi, P. P. (2019) · Biomolecules · doi:10.3390/biom9040153 · Cited by 303
Lu, S., Dong, X., Jian, H., Chen, J., Chen, G., Sun, Y., Ji, Y., Wang, Z., Shi, J., Lu, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02641 · Cited by 303
Kawamura, M., McVicar, D. W., Johnston, J. A., Blake, T. B., Chen, Y. Q., Lal, B. K., Lloyd, A. R., Kelvin, D. J., Staples, J. E., Ortaldo, J. R., et al. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6374 · Cited by 302
Obesity, Diabetes, and Increased Cancer Progression
Kim, D.-S., & Scherer, P. E. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0077 · Cited by 302
Reuter, C. W. M., Morgan, M. A., & Bergmann, L. (2000) · Blood · doi:10.1182/blood.v96.5.1655 · Cited by 300
Pietra, D., Li, S., Brisci, A., Passamonti, F., Rumi, E., Theocharides, A., Ferrari, M., Gisslinger, H., Kralovics, R., Cremonesi, L., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101576 · Cited by 298
Enomoto, H., Crawford, P. A., Gorodinsky, A., Heuckeroth, R. O., Johnson, E. M., & Milbrandt, J. (2001) · Development · doi:10.1242/dev.128.20.3963 · Cited by 298
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Kiyoi, H., Kawashima, N., & Ishikawa, Y. (2020) · Cancer Science · doi:10.1111/cas.14274 · Cited by 298
Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia
Rajala, H. L. M., Eldfors, S., Kuusanmäki, H., van Adrichem, A. J., Olson, T., Lagström, S., Andersson, E. I., Jerez, A., Clemente, M. J., Yan, Y., et al. (2013) · Blood · doi:10.1182/blood-2012-12-474577 · Cited by 294
Zebrafish models of idiopathic scoliosis link cerebrospinal fluid flow defects to spine curvature
Grimes, D. T., Boswell, C. W., Morante, N. F. C., Henkelman, R. M., Burdine, R. D., & Ciruna, B. (2016) · Science · doi:10.1126/science.aaf6419 · Cited by 294
Yang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
Rimkunas, V. M., Crosby, K. E., Li, D., Hu, Y., Kelly, M. E., Gu, T.-L., Mack, J. S., Silver, M. R., Zhou, X., & Haack, H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3351 · Cited by 293
Wnt–Ryk signalling mediates medial–lateral retinotectal topographic mapping
Schmitt, A. M., Shi, J., Wolf, A. M., Lu, C.-C., King, L. A., & Zou, Y. (2006) · Nature · doi:10.1038/nature04334 · Cited by 292
MEK and the inhibitors: from bench to bedside
Akinleye, A., Furqan, M., Mukhi, N., Ravella, P., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-27 · Cited by 291
Arock, M., Sotlar, K., Akin, C., Broesby-Olsen, S., Hoermann, G., Escribano, L., Kristensen, T. K., Kluin-Nelemans, H. C., Hermine, O., Dubreuil, P., et al. (2015) · Leukemia · doi:10.1038/leu.2015.24 · Cited by 290
Physiological functions of protein kinase B/Akt
Yang, Z.-Z., Tschopp, O., Baudry, A., Dümmler, B., Hynx, D., & Hemmings, B. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320350 · Cited by 283
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 282
Kakadia, S., Yarlagadda, N., Awad, R., Kundranda, M., Niu, J., Naraev, B., Mina, L., Dragovich, T., Gimbel, M., & Mahmoud, F. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s182721 · Cited by 277
Schnürch, H., & Risau, W. (1993) · Development · doi:10.1242/dev.119.3.957 · Cited by 277
Prenen, H., Cools, J., Mentens, N., Folens, C., Sciot, R., Schöffski, P., Van Oosterom, A., Marynen, P., & Debiec-Rychter, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2275 · Cited by 274
KDR Activating Mutations in Human Angiosarcomas Are Sensitive to Specific Kinase Inhibitors
Antonescu, C. R., Yoshida, A., Guo, T., Chang, N.-E., Zhang, L., Agaram, N. P., Qin, L.-X., Brennan, M. F., Singer, S., & Maki, R. G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2068 · Cited by 274
Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
Blumenschein, G. R., Mills, G. B., & Gonzalez-Angulo, A. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3774 · Cited by 273
Golding, B., Luu, A., Jones, R., & Viloria-Petit, A. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0810-4 · Cited by 273
A novel family of cell surface receptors with tyrosine kinase-like domain.
Masiakowski, P., & Carroll, R. D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)35733-8 · Cited by 272
DeAngelo, D. J., Stone, R. M., Heaney, M. L., Nimer, S. D., Paquette, R. L., Klisovic, R. B., Caligiuri, M. A., Cooper, M. R., Lecerf, J.-M., Karol, M. D., et al. (2006) · Blood · doi:10.1182/blood-2006-02-005702 · Cited by 272
The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism
Labrador, J. P., Azcoitia, V., Tuckermann, J., Lin, C., Olaso, E., Mañes, S., Brückner, K., Goergen, J., Lemke, G., Yancopoulos, G., et al. (2001) · EMBO reports · doi:10.1093/embo-reports/kve094 · Cited by 271
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Rankin, E. B., Fuh, K. C., Castellini, L., Viswanathan, K., Finger, E. C., Diep, A. N., LaGory, E. L., Kariolis, M. S., Chan, A., Lindgren, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404848111 · Cited by 269
Signal Transducer and Activator of Transcription 3 in Liver Diseases: A Novel Therapeutic Target
Wang, H., Lafdil, F., Kong, X., & Gao, B. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.536 · Cited by 269
Gainor, J. F., Tseng, D., Yoda, S., Dagogo-Jack, I., Friboulet, L., Lin, J. J., Hubbeling, H. G., Dardaei, L., Farago, A. F., Schultz, K. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00063 · Cited by 264
Motzer, R. J., Porta, C., Vogelzang, N. J., Sternberg, C. N., Szczylik, C., Zolnierek, J., Kollmannsberger, C., Rha, S. Y., Bjarnason, G. A., Melichar, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70030-0 · Cited by 262
Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases
HAFIZI, S., & DAHLBACK, B. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.04.004 · Cited by 261
New Insights into the Mechanism of Wnt Signaling Pathway Activation
(2011) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-386035-4.00002-1 · Cited by 260
Carlomagno, F., Guida, T., Anaganti, S., Vecchio, G., Fusco, A., Ryan, A. J., Billaud, M., & Santoro, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207810 · Cited by 258
Wu, Y.-L., Cheng, Y., Zhou, J., Lu, S., Zhang, Y., Zhao, J., Kim, D.-W., Soo, R. A., Kim, S.-W., Pan, H., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30154-5 · Cited by 258
Regulation of Angiogenesis by Eph–Ephrin Interactions
Kuijper, S., Turner, C. J., & Adams, R. H. (2007) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2007.03.003 · Cited by 257
Li, A. Y., McCusker, M. G., Russo, A., Scilla, K. A., Gittens, A., Arensmeyer, K., Mehra, R., Adamo, V., & Rolfo, C. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101911 · Cited by 257
Obesity, Type 2 Diabetes, and Cancer Risk
Scully, T., Ettela, A., LeRoith, D., & Gallagher, E. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.615375 · Cited by 256
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
The Role of Insulin Receptor Isoforms and Hybrid Insulin/IGF-I Receptors in Human Cancer
Belfiore, A. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207780249173 · Cited by 252
Haling, J. R., Sudhamsu, J., Yen, I., Sideris, S., Sandoval, W., Phung, W., Bravo, B. J., Giannetti, A. M., Peck, A., Masselot, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.007 · Cited by 252
Imamura, Y., Morikawa, T., Liao, X., Lochhead, P., Kuchiba, A., Yamauchi, M., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., Haigis, K. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3210 · Cited by 249
Shiota, M., Fujimoto, J., Semba, T., Satoh, H., Yamamoto, T. S., & Mori, S. (1994) · PubMed · Cited by 246
Kan, M., Zhang, G., Zarnegar, R., Michalopoulos, G., Myoken, Y., McKeehan, W. L., & Stevens, J. L. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)90524-b · Cited by 246
Ueda, S., Ogata, S., Tsuda, H., Kawarabayashi, N., Kimura, M., Sugiura, Y., Tamai, S., Matsubara, O., Hatsuse, K., & Mochizuki, H. (2004) · Pancreas · doi:10.1097/00006676-200407000-00061 · Cited by 245
Reeves, R., Edberg, D. D., & Li, Y. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.2.575-594.2001 · Cited by 242
Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404639111 · Cited by 242
Cassier, P. A., Fumagalli, E., Rutkowski, P., Schöffski, P., Van Glabbeke, M., Debiec-Rychter, M., Emile, J.-F., Duffaud, F., Martin-Broto, J., Landi, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3025 · Cited by 239
Hepatocyte growth factor/MET in cancer progression and biomarker discovery
Matsumoto, K., Umitsu, M., De Silva, D. M., Roy, A., & Bottaro, D. P. (2017) · Cancer Science · doi:10.1111/cas.13156 · Cited by 239
Baskar, S., Kwong, K. Y., Hofer, T., Levy, J. M., Kennedy, M. G., Lee, E., Staudt, L. M., Wilson, W. H., Wiestner, A., & Rader, C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1823 · Cited by 238
Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas
Paugh, B. S., Zhu, X., Qu, C., Endersby, R., Diaz, A. K., Zhang, J., Bax, D. A., Carvalho, D., Reis, R. M., Onar-Thomas, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1491 · Cited by 235
Structure and function of VEGF receptors
Stuttfeld, E., & Ballmer‐Hofer, K. (2009) · IUBMB Life · doi:10.1002/iub.234 · Cited by 234
Chi, X., Michos, O., Shakya, R., Riccio, P., Enomoto, H., Licht, J. D., Asai, N., Takahashi, M., Ohgami, N., Kato, M., et al. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.07.013 · Cited by 233
Shi, Y., Chen, G., Wang, X., Liu, Y., Wu, L., Hao, Y., Liu, C., Zhu, S., Zhang, X., Li, Y., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00168-0 · Cited by 233
ErbB-3 Predicts Survival in Ovarian Cancer
Tanner, B., Hasenclever, D., Stern, K., Schormann, W., Bezler, M., Hermes, M., Brulport, M., Bauer, A., Schiffer, I. B., Gebhard, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8397 · Cited by 231
Recurrent KRAS codon 146 mutations in human colorectal cancer
Edkins, S., & O’Meara, S. (2006) · Cancer Biology & Therapy · doi:10.4161/cbt.5.8.3251 · Cited by 229
Tomasson, M. H., Xiang, Z., Walgren, R., Zhao, Y., Kasai, Y., Miner, T., Ries, R. E., Lubman, O., Fremont, D. H., McLellan, M. D., et al. (2008) · Blood · doi:10.1182/blood-2007-09-113027 · Cited by 227
EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
Suda, K., Onozato, R., Yatabe, Y., & Mitsudomi, T. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181913c9f · Cited by 226
Resistance to Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors
Gramza, A. W., Corless, C. L., & Heinrich, M. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0190 · Cited by 226
Emerging strategies to target RAS signaling in human cancer therapy
Chen, K., Zhang, Y., Qian, L., & Wang, P. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01127-w · Cited by 226
Bazan, V., Migliavacca, M., Zanna, I., Tubiolo, C., Grassi, N., Latteri, M. A., La Farina, M., Albanese, I., Dardanoni, G., Salerno, S., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf226 · Cited by 225
Mayr, D., Hirschmann, A., Löhrs, U., & Diebold, J. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.05.029 · Cited by 224
Soverini, S., Mancini, M., Bavaro, L., Cavo, M., & Martinelli, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0780-6 · Cited by 222
FMS mutations in myelodysplastic, leukemic, and normal subjects.
Ridge, S. A., Worwood, M., Oscier, D., Jacobs, A., & Padua, R. A. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.4.1377 · Cited by 220
Yano, S., Yamada, T., Takeuchi, S., Tachibana, K., Minami, Y., Yatabe, Y., Mitsudomi, T., Tanaka, H., Kimura, T., Kudoh, S., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823ab0dd · Cited by 220
Expression and rearrangement of the ROS1 gene in human glioblastoma cells.
Birchmeier, C., Sharma, S., & Wigler, M. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9270 · Cited by 219
Heinrich, M. C., Griffith, D., McKinley, A., Patterson, J., Presnell, A., Ramachandran, A., & Debiec-Rychter, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0625 · Cited by 219
Receptor tyrosine kinase activation: From the ligand perspective
Trenker, R., & Jura, N. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.01.016 · Cited by 219
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 218
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas
Ozawa, T., Brennan, C. W., Wang, L., Squatrito, M., Sasayama, T., Nakada, M., Huse, J. T., Pedraza, A., Utsuki, S., Yasui, Y., et al. (2010) · Genes & Development · doi:10.1101/gad.1972310 · Cited by 217
The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression
Ragimbeau, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg038 · Cited by 215
Bridgeman, V. L., Vermeulen, P. B., Foo, S., Bilecz, A., Daley, F., Kostaras, E., Nathan, M. R., Wan, E., Frentzas, S., Schweiger, T., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4845 · Cited by 214
Elevated Serum Concentrations of Hepatocyte Growth Factor in Patients With Multiple Myeloma
Seidel, C., Børset, M., Turesson, I., Abildgaard, N., Sundan, A., & e Nordic Myeloma Study Group, A. W. F. T. (1998) · Blood · doi:10.1182/blood.v91.3.806 · Cited by 214
Defective downregulation of receptor tyrosine kinases in cancer
Bache, K. G., Slagsvold, T., & Stenmark, H. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600292 · Cited by 212
du Bois, A., Kristensen, G., Ray-Coquard, I., Reuss, A., Pignata, S., Colombo, N., Denison, U., Vergote, I., del Campo, J. M., Ottevanger, P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00366-6 · Cited by 211
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges
Ascione, C. M., Napolitano, F., Esposito, D., Servetto, A., Belli, S., Santaniello, A., Scagliarini, S., Crocetto, F., Bianco, R., & Formisano, L. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102530 · Cited by 211
Zhou, Y.-Q., He, C., Chen, Y.-Q., Wang, D., & Wang, M.-H. (2003) · Oncogene · doi:10.1038/sj.onc.1206075 · Cited by 210
Sang, J., Acquaviva, J., Friedland, J. C., Smith, D. L., Sequeira, M., Zhang, C., Jiang, Q., Xue, L., Lovly, C. M., Jimenez, J.-P., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0440 · Cited by 208
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Torino, F., Corsello, S. M., Longo, R., Barnabei, A., & Gasparini, G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.4 · Cited by 207
Ephrin signaling in vivo: Look both ways
Davy, A., & Soriano, P. (2005) · Developmental Dynamics · doi:10.1002/dvdy.20200 · Cited by 207
Clarke, C. N., & Kopetz, S. (2015) · PubMed · doi:10.3978/j.issn.2078-6891.2015.077 · Cited by 207
Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches
Saraon, P., Pathmanathan, S., Snider, J., Lyakisheva, A., Wong, V., & Stagljar, I. (2021) · Oncogene · doi:10.1038/s41388-021-01841-2 · Cited by 205
Bixby, D., & Talpaz, M. (2009) · Hematology · doi:10.1182/asheducation-2009.1.461 · Cited by 204
Kim, S. M., Kwon, O.-J., Hong, Y. K., Kim, J. H., Solca, F., Ha, S.-J., Soo, R. A., Christensen, J. G., Lee, J. H., & Cho, B. C. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0311 · Cited by 202
Angiopoietin–Tie signalling in the cardiovascular and lymphatic systems
Eklund, L., Kangas, J., & Saharinen, P. (2017) · Clinical Science · doi:10.1042/cs20160129 · Cited by 202
Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers
Jeong, E. G., Kim, M. S., Nam, H. K., Min, C. K., Lee, S., Chung, Y. J., Yoo, N. J., & Lee, S. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4839 · Cited by 201
Distribution of the Mammalian Stat Gene Family in Mouse Chromosomes
Copeland, N. G., Gilbert, D. J., Schindler, C., Zhong, Z., Wen, Z., Darnell, J. E., Mui, A. L.-F., Miyajima, A., Quelle, F. W., Ihle, J. N., et al. (1995) · Genomics · doi:10.1006/geno.1995.1235 · Cited by 199
Functional Analysis of c-Met/Hepatocyte Growth Factor Pathway in Malignant Pleural Mesothelioma
Jagadeeswaran, R., Ma, P. C., Seiwert, T. Y., Jagadeeswaran, S., Zumba, O., Nallasura, V., Ahmed, S., Filiberti, R., Paganuzzi, M., Puntoni, R., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-04-4567 · Cited by 198
Xu, J., Shen, L., Bai, C., Wang, W., Li, J., Yu, X., Li, Z., Li, E., Yuan, X., Chi, Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30493-9 · Cited by 197
The Role of Ryk and Ror Receptor Tyrosine Kinases in Wnt Signal Transduction
Green, J., Nusse, R., & van Amerongen, R. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009175 · Cited by 196
MET As a Possible Target for Non–Small-Cell Lung Cancer
Sadiq, A. A., & Salgia, R. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.9422 · Cited by 195
NRAS Mutations Are Rare in Colorectal Cancer
Irahara, N., Baba, Y., Nosho, K., Shima, K., Yan, L., Dias-Santagata, D., Iafrate, A. J., Fuchs, C. S., Haigis, K. M., & Ogino, S. (2010) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3181c93fd1 · Cited by 194
The STAT3 pathway as a therapeutic target in head and neck cancer: barriers and innovations
Geiger, J. L., Grandis, J. R., & Bauman, J. E. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2015.11.022 · Cited by 193
Arrieta, O., Cardona, A. F., Martín, C., Más-López, L., Corrales-Rodríguez, L., Bramuglia, G., Castillo-Fernandez, O., Meyerson, M., Amieva-Rivera, E., Campos-Parra, A. D., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000481 · Cited by 193
Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications
Wei, Q., Qian, Y., Yu, J., & Wong, C. C. (2020) · Oncogene · doi:10.1038/s41388-020-01432-7 · Cited by 191
Germline mutation of RET codon 883 in two cases of de novo MEN 2B
Smith, D. P., Houghton, C., & Ponder, B. A. (1997) · Oncogene · doi:10.1038/sj.onc.1201481 · Cited by 189
Bilsland, J. G., Wheeldon, A., Mead, A., Znamenskiy, P., Almond, S., Waters, K. A., Thakur, M., Beaumont, V., Bonnert, T. P., Heavens, R., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301446 · Cited by 188
Joensuu, H., Wardelmann, E., Sihto, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hartmann, J. T., Pink, D., Cameron, S., Hohenberger, P., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5751 · Cited by 187
Oh, S., Mao, X., Manfredo-Vieira, S., Lee, J., Patel, D., Choi, E. J., Alvarado, A., Cottman-Thomas, E., Maseda, D., Tsao, P. Y., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01637-z · Cited by 186
Asai, N., Murakami, H., Iwashita, T., & Takahashi, M. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.30.17644 · Cited by 184
Whole‐exome sequencing of pancreatic neoplasms with acinar differentiation
Jiao, Y., Yonescu, R., Offerhaus, G. J. A., Klimstra, D. S., Maitra, A., Eshleman, J. R., Herman, J. G., Poh, W., Pelosof, L., Wolfgang, C. L., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4310 · Cited by 184
The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy
Mabeta, P., & Steenkamp, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415585 · Cited by 183
c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases
Zeng, Z.-S., Weiser, M. R., Kuntz, E., Chen, C.-T., Khan, S. A., Forslund, A., Nash, G. M., Gimbel, M., Yamaguchi, Y., Culliford, A. T., et al. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.049 · Cited by 180
Hecht, J. R., Trarbach, T., Hainsworth, J. D., Major, P., Jäger, E., Wolff, R. A., Lloyd-Salvant, K., Bodoky, G., Pendergrass, K., Berg, W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.4496 · Cited by 178
Yochum, Z. A., Cades, J., Wang, H., Chatterjee, S., Simons, B. W., O’Brien, J. P., Khetarpal, S. K., Lemtiri-Chlieh, G., Myers, K. V., Huang, E. H.-B., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0482-y · Cited by 178
Tubby and tubby‐like protein 1 are new MerTK ligands for phagocytosis
Caberoy, N. B., Zhou, Y., & Li, W. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.265 · Cited by 177
DaneshManesh, A. H., Mikaelsson, E., Jeddi‐Tehrani, M., Bayat, A. A., Ghods, R., Ostadkarampour, M., Akhondi, M., Lagercrantz, S., Larsson, C., Österborg, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23587 · Cited by 177
A Recurrent PDGFRB Mutation Causes Familial Infantile Myofibromatosis
Cheung, Y. H., Gayden, T., Campeau, P. M., LeDuc, C. A., Russo, D., Nguyen, V.-H., Guo, J., Qi, M., Guan, Y., Albrecht, S., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.04.026 · Cited by 174
Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173
Cremolini, C., Bartolomeo, M. D., Amatu, A., Antoniotti, C., Moretto, R., Berenato, R., Perrone, F., Tamborini, E., Aprile, G., Lonardi, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv290 · Cited by 173
Receptor Tyrosine Kinase Coactivation Networks in Cancer
Xu, A. M., & Huang, P. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0163 · Cited by 173
A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Shi, H., Hong, A., Kong, X., Koya, R. C., Song, C., Moriceau, G., Hugo, W., Yu, C. C., Ng, C., Chodon, T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0279 · Cited by 173
Hammers, H. J., Verheul, H. M., Salumbides, B., Sharma, R., Rudek, M., Jaspers, J., Shah, P., Ellis, L., Shen, L., Paesante, S., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1106 · Cited by 173
Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk
Halford, M. M., Armes, J., Buchert, M., Meskenaite, V., Grail, D., Hibbs, M. L., Wilks, A. F., Farlie, P. G., Newgreen, D. F., Hovens, C. M., et al. (2000) · Nature Genetics · doi:10.1038/78099 · Cited by 172
Hartmaier, R. J., Markovets, A. A., Ahn, M. J., Sequist, L. V., Han, J.-Y., Cho, B. C., Yu, H. A., Kim, S.-W., Yang, J. C.-H., Lee, J.-S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0586 · Cited by 172
Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
Dev, S. S., Abidin, S. A. Z., Farghadani, R., Othman, I., & Naidu, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.772510 · Cited by 171
Cho, B. C., Ahn, M., Kang, J. H., Soo, R. A., Reungwetwattana, T., Yang, J. C., Çiçin, İ., Kim, D., Wu, Y.-L. L. C., Lü, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00515 · Cited by 171
Crystal Structure of the MuSK Tyrosine Kinase
Till, J. H., Becerra, M., Watty, A., Lu, Y., Ma, Y., Neubert, T. A., Burden, S. J., & Hubbard, S. R. (2002) · Structure · doi:10.1016/s0969-2126(02)00814-6 · Cited by 169
Redox regulation of protein kinases
Truong, T. H., & Carroll, K. S. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.790873 · Cited by 169
Emerging BRAF Mutations in Cancer Progression and Their Possible Effects on Transcriptional Networks
Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020) · Genes · doi:10.3390/genes11111342 · Cited by 168
HER3 Is a Determinant for Poor Prognosis in Melanoma
Reschke, M., Mihic-Probst, D., van der Horst, E. H., Knyazev, P., Wild, P. J., Hutterer, M., Meyer, S., Dummer, R., Moch, H., & Ullrich, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0186 · Cited by 168
The Receptor Tyrosine Kinase AXL in Cancer Progression
Rankin, E., & Giaccia, A. (2016) · Cancers · doi:10.3390/cancers8110103 · Cited by 168
Receptor tyrosine kinase inhibitors in cancer
Ebrahimi, N., Fardi, E., Ghaderi, H., Palizdar, S., Khorram, R., Vafadar, R., Ghanaatian, M., Rezaei‐Tazangi, F., Baziyar, P., Ahmadi, A., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04729-4 · Cited by 168
Ron, C., Khatri, P., Mazur, P. K., Polin, M., Zheng, Y., Vaka, D., Hoang, C. D., Shrager, J. B., Xu, Y., Vicent, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2775 · Cited by 167
Gallo, L. H., Nelson, K. N., Meyer, A. N., & Donoghue, D. J. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.03.003 · Cited by 166
Drilon, A., Somwar, R., Wagner, J. P., Vellore, N. A., Eide, C. A., Zabriskie, M. S., Arcila, M. E., Hechtman, J. F., Wang, L., Smith, R. S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2013 · Cited by 166
Tumor microenvironment-mediated immune tolerance in development and treatment of gastric cancer
Liu, Y., Li, C., Lu, Y., Liu, C., & Yang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1016817 · Cited by 166
McIntyre, A., Summersgill, B., Grygalewicz, B., Gillis, A. J. M., Stoop, J., van Gurp, R. J. H. L. M., Dennis, N., Fisher, C., Huddart, R., Cooper, C., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0471 · Cited by 165
High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia
Cui, B., Ghia, E. M., Chen, L., Rassenti, L. Z., DeBoever, C., Widhopf, G. F., Yu, J., Neuberg, D. S., Wierda, W. G., Rai, K. R., et al. (2016) · Blood · doi:10.1182/blood-2016-04-712562 · Cited by 164
Sensi, M., Catani, M., Castellano, G., Nicolini, G., Alciato, F., Tragni, G., Santis, G. D., Bersani, I., Avanzi, G., Tomassetti, A., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.218 · Cited by 163
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
Guan, J., Umapathy, G., Yamazaki, Y., Wolfstetter, G., Mendoza-García, P., Pfeifer, K., Mohammed, A., Hugosson, F., Zhang, H., Hsu, A. W., et al. (2015) · eLife · doi:10.7554/elife.09811 · Cited by 163
Damelin, M., Bankovich, A., Bernstein, J., Lucas, J., Chen, L., Williams, S., Park, A., Aguilar, J., Ernstoff, E., Charati, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2611 · Cited by 163
Fibroblast Growth Factor Receptor 2 (FGFR2) Mutation Related Syndromic Craniosynostosis
Azoury, S. C., Reddy, S., Shukla, V., & Deng, C. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.22373 · Cited by 163
Desbois‐Mouthon, C., Baron, A., Eggelpoël, M.-J. B.-V., Fartoux, L., Venot, C., Bladt, F., Housset, C., & Rosmorduc, O. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2980 · Cited by 162
Reshetnyak, A. V., Murray, P. B., Shi, X., Mo, E. S., Mohanty, J., Tomé, F., Bai, H., Günel, M., Lax, I., & Schlessinger, J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520099112 · Cited by 162
Interaction of the TEK and TIE receptor tyrosine kinases during cardiovascular development
Puri, M. C., Partanen, J., Rossant, J., & Bernstein, A. (1999) · Development · doi:10.1242/dev.126.20.4569 · Cited by 161
EphrinB/EphB Signaling Controls Embryonic Germ Layer Separation by Contact-Induced Cell Detachment
Rohani, N., Canty, L., Luu, O., Fagotto, F., & Winklbauer, R. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1000597 · Cited by 161
Maroun, J. A., Anthony, L. B., Blais, N., Burkes, R., Dowden, S. D., Dranitsaris, G., Samson, B., Shah, A., Thirlwell, M. P., Vincent, M. D., et al. (2007) · Current Oncology · doi:10.3747/co.2007.96 · Cited by 161
Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family.
Mossie, K. G., Jallal, B., Alves, F., Sures, I., Plowman, G. D., & Ullrich, A. (1995) · PubMed · Cited by 161
EGFR: An essential receptor tyrosine kinase-regulator of cancer stem cells
(2020) · Advances in Cancer Research · doi:10.1016/bs.acr.2020.04.003 · Cited by 161
Liu, X., Vega, Q. C., Decker, R. A., Pandey, A., Worby, C. A., & Dixon, J. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.10.5309 · Cited by 160
Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer
Arienti, C., Pignatta, S., & Tesei, A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01308 · Cited by 160
Ward, C. W., & Lawrence, M. C. (2009) · BioEssays · doi:10.1002/bies.200800210 · Cited by 159
The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors
Alexander, S. P., Fabbro, D., Kelly, E., Marrion, N., Peters, J. A., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Southan, C., et al. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13353 · Cited by 159
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors
Razavi, P., Dickler, M. N., Shah, P. D., Toy, W., Brown, D. N., Won, H. H., Li, B. T., Shen, R., Vasan, N., Modi, S., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-0047-1 · Cited by 159
Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]
Ludwig, H., Nachbaur, D., Fritz, E., Krainer, M., & Huber, H. (1991) · Blood · doi:10.1182/blood.v77.12.2794.2794 · Cited by 158
A Global Analysis of the Receptor Tyrosine Kinase-Protein Phosphatase Interactome
Yao, Z., Darowski, K. D., St‐Denis, N., Wong, V., Offensperger, F., Villedieu, A., Amin, S., Malty, R. H., Aoki, H., Guo, H., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2016.12.004 · Cited by 155
Role and targeting of anaplastic lymphoma kinase in cancer
Corte, C. M. D., Viscardi, G., Liello, R. D., Fasano, M., Martinelli, E., Troiani, T., Ciardiello, F., & Morgillo, F. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0776-2 · Cited by 155
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
Gomatou, G., Syrigos, N. K., & Kotteas, E. A. (2023) · Cancers · doi:10.3390/cancers15030841 · Cited by 155
Mining for JAK–STAT mutations in cancer
Constantinescu, S. N., Girardot, M., & Pecquet, C. (2008) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2007.12.002 · Cited by 154
Sánchez‐Solana, B., Laborda, J., & Baladrón, V. (2011) · Molecular Endocrinology · doi:10.1210/me.2011-1027 · Cited by 154
Ephrins and Eph receptors in stem cells and cancer
Genander, M., & Frisén, J. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.08.005 · Cited by 154
Interaction of musleblind, CUG‐BP1 and hnRNP H proteins in DM1‐associated aberrant IR splicing
Paul, S., Dansithong, W., Kim, D., Rossi, J. J., Webster, N. J. G., Comai, L., & Reddy, S. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601296 · Cited by 153
Expression and Nuclear Localization of ErbB3 in Prostate Cancer
Koumakpayi, I. H., Diallo, J., Page, C. L., Lessard, L., Gleave, M. E., Bégin, L. R., Mes‐Masson, A., & Fred Saad, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2242 · Cited by 151
The Role of PDGFs and PDGFRs in Colorectal Cancer
Manzat-Saplacan, R. M., Bălăcescu, L., Gherman, C. D., Chira, R. I., Anca, C., Mircea, P. A., Lisencu, C. I., & Bălăcescu, O. (2017) · Mediators of Inflammation · doi:10.1155/2017/4708076 · Cited by 151
Zhang, Z., Zhou, X., Shen, H., Wang, D., & Wang, Y. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-41 · Cited by 150
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties
Gao, Y., Chang, M. T., McKay, D., Na, N., Zhou, B., Yaeger, R. D., Torres, N. M., Muniz, K., Drosten, M., Barbacid, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1452 · Cited by 148
PDGF receptor mutations in human diseases
Guérit, E. M., Arts, F. A., Dachy, G., Boulouadnine, B., & Demoulin, J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03753-y · Cited by 148
VEGFR-2 conformational switch in response to ligand binding
Sarabipour, S., Ballmer‐Hofer, K., & Hristova, K. A. (2016) · eLife · doi:10.7554/elife.13876 · Cited by 147
Vessel co-option and resistance to anti-angiogenic therapy
Kuczynski, E. A., & Reynolds, A. R. (2019) · Angiogenesis · doi:10.1007/s10456-019-09698-6 · Cited by 147
Role and Significance of c-KIT Receptor Tyrosine Kinase in Cancer: A Review
Sheikh, E., Tran, T. T., Vranić, S., Levy, A., & Bonfil, R. D. (2022) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2021.7399 · Cited by 147
Axon routing across the midline controlled by the Drosophila Derailed receptor
Bonkowsky, J. L., Yoshikawa, S., O’Keefe, D. D., Scully, A. L., & Thomas, J. B. (1999) · Nature · doi:10.1038/990122 · Cited by 146
Ford, C. E., Lau, S. A., Zhu, C., Andersson, T., Tsao, M., & Vogel, W. F. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603614 · Cited by 146
Activating mutations in human acute megakaryoblastic leukemia
Malinge, S., Ragu, C., Della-Valle, V., Pisani, D. F., Constantinescu, S. N., Pérez, C., Villeval, J., Reinhardt, D., Landman‐Parker, J., Michaux, L., et al. (2008) · Blood · doi:10.1182/blood-2008-01-136366 · Cited by 145
Genetic landscape of papillary thyroid carcinoma in the Chinese population
Liang, J., Cai, W., Feng, D., Teng, H., Mao, F., Jiang, Y., Hu, S., Li, X., Zhang, Y., Liu, B., et al. (2017) · The Journal of Pathology · doi:10.1002/path.5005 · Cited by 145
Lin, J. J., Choudhury, N. J., Yoda, S., Zhu, V. W., Johnson, T. W., Sakhtemani, R., Dagogo-Jack, I., Digumarthy, S. R., Lee, C., Do, A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0032 · Cited by 145
Omholt, K., Karsberg, S., Platz, A., Kanter, L., Ringborg, U. K., & Hansson, J. (2002) · PubMed · Cited by 144
Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling
Ferguson, H. R., Smith, M. P., & Francavilla, C. (2021) · Cells · doi:10.3390/cells10051201 · Cited by 144
Navigating the ERK1/2 MAPK Cascade
Martín-Vega, A., & Cobb, M. H. (2023) · Biomolecules · doi:10.3390/biom13101555 · Cited by 144
Reindl, C., Bagrintseva, K., Vempati, S., Schnittger, S., Ellwart, J. W., Wenig, K., Hopfner, K., Hiddemann, W., & Spiekermann, K. (2006) · Blood · doi:10.1182/blood-2005-06-2596 · Cited by 143
Szűcs, Z., Thway, K., Fisher, C., Bulusu, R., Constantinidou, A., Benson, C., van der Graaf, W. T. A., & Jones, R. L. (2016) · Future Oncology · doi:10.2217/fon-2016-0192 · Cited by 138
Kim, G., Her, J.-H., & Han, J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200710188 · Cited by 137
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 137
The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention
Menck, K., Heinrichs, S., Baden, C., & Bleckmann, A. (2021) · Cells · doi:10.3390/cells10010142 · Cited by 137
Hedger, G., Sansom, M. S. P., & Koldsø, H. (2015) · Scientific Reports · doi:10.1038/srep09198 · Cited by 136
Xie, Q. R., Bradley, R., Kang, L., Koeman, J. M., Ascierto, M. L., Worschech, A., Giorgi, V. D., Wang, E., Kefene, L., Su, Y., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119059109 · Cited by 136
Jain, S. R., Naughton, C. K., Yang, M., Strickland, A. M., Vij, K. R., Encinas, M., Golden, J., Gupta, A. K., Heuckeroth, R. O., Johnson, E. M., et al. (2004) · Development · doi:10.1242/dev.01421 · Cited by 136
Mohan, C. D., Srinivasa, V., Rangappa, S., Mervin, L., Mohan, S., Paricharak, S., Baday, S., Li, F., Shanmugam, M. K., Chinnathambi, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153155 · Cited by 136
KIT and Melanoma: Biological Insights and Clinical Implications
Pham, D. D. M., Guhan, S. M., & Tsao, H. (2020) · Yonsei Medical Journal · doi:10.3349/ymj.2020.61.7.562 · Cited by 136
Mudduluru, G., Vajkoczy, P., & Allgayer, H. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0326 · Cited by 135
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Cortot, A. B., Kherrouche, Z., Descarpentries, C., Wislez, M., Baldacci, S., Furlan, A., & Tulasne, D. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw262 · Cited by 135
Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer
Jin, N., Bi, A., Lan, X., Xu, J., Wang, X., Liu, Y., Wang, T., Tang, S., Zeng, H., Chen, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10427-2 · Cited by 135
Zhao, H., Yao, W., Min, X., Gu, K., Yu, G., Zhang, Z., Cui, J., Miao, L., Zhang, L., Yuan, X., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.006 · Cited by 131
Andre, P., Wang, Q., Wang, N., Gao, B., Schilit, A., Halford, M. M., Stacker, S. A., Zhang, X., & Yang, Y. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.414441 · Cited by 130
Expression of a functional human insulin receptor from a cloned cDNA in Chinese hamster ovary cells.
Ebina, Y., Edery, M., Ellis, L., Standring, D. N., Beaudoin, J. D., Roth, R. A., & Rutter, W. J. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.8014 · Cited by 129
Xie, L., Xu, J., Sun, X., Tang, X., Yan, T., Yang, R., & Guo, W. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0542 · Cited by 128
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
Tomlinson, D. C., Hurst, C. D., & Knowles, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210399 · Cited by 128
MET: A Critical Player in Tumorigenesis and Therapeutic Target
Graveel, C. R., Tolbert, D., & Vande Woude, G. F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009209 · Cited by 128
Montor, W. R., Salas, A. R. O. S. E., & de Melo, F. H. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0792-2 · Cited by 128
de Miguel, F. J., Gentile, C., Feng, W. W., Silva, S. J., Sankar, A., Expósito, F., Cai, W. L., Melnick, M. A., Robles-Oteíza, C., Hinkley, M. M., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.005 · Cited by 128
The RTK Interactome: Overview and Perspective on RTK Heterointeractions
Paul, M. D., & Hristova, K. A. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00467 · Cited by 127
Camidge, D. R., Barlési, F., Goldman, J. W., Morgensztern, D., Heist, R. S., Vokes, E. E., Spira, A. I., Angevin, E., Su, W., Hong, D. S., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00739 · Cited by 127
Faoro, L. N., Singleton, P. A., Cervantes, G. M., Lennon, F. E., Choong, N. W., Kanteti, R., Ferguson, B. D., Husain, A. N., Tretiakova, M., Ramnath, N., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.075085 · Cited by 126
Kim, H. R., Kim, W. S., Choi, Y. J., Choi, C., Rho, J. K., & Lee, J. C. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.08.001 · Cited by 126
Musso, T., Johnston, J. A., Linnekin, D., Varesio, L., Rowe, T. K., O’Shea, J. J., & McVicar, D. W. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.4.1425 · Cited by 125
Cho, B. C., Kim, D., Spira, A. I., Gomez, J. E., Haura, E. B., Kim, S., Sanborn, R. E., Cho, E. K., Lee, K. H., Minchom, A. R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02554-7 · Cited by 125
ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
Goetz, E. M., Ghandi, M., Treacy, D. J., Wagle, N., & Garraway, L. A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2073 · Cited by 123
Cheng, H.-L., Liu, H.-S., Lin, Y. J., Chen, H. H. W., Hsu, P.-Y., Chang, T.-Y., HO, C.-L., Tzai, T.-S., & Chow, N.-H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602593 · Cited by 123
Cited by
Targeting PP2A in cancer: an underrated option
Sarais, F., Krempien, F., Koehn, C., Brewing, L., Classen, C. F., Walter, M., & Shokraie, O. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03560-y · Cited by 8
Metadata
- Authors
- Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-08-14
- Volume
- 9
- Issue
- 1
- Pages
- 201-201
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4401593620
- Cited by
- 260
- References
- 859
- FWCI
- 68.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.